Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis
Advanced Science · 2025
DOI: 10.1002/advs.202409416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongmei Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Hunan Provincial Health High-Level Talent Scientific Research Project.
Abstract (Originalsprache)
There is an urgent necessity to devise efficient tactics to tackle the inevitable development of resistance to osimertinib, which is a third‐generation epidermal growth factor receptor (EGFR) inhibitor used in treating EGFR‐mutant nonsmall cell lung cancer (NSCLC). This study demonstrates that combining itraconazole with osimertinib synergistically reduces the proliferation and migration, enhances the apoptosis of osimertinib‐resistant cells, and effectively inhibits the growth of osimertinib‐resistant tumors. Mechanistically, itraconazole combined with osimertinib promotes the proteasomal degradation of sonic hedgehog (SHH), resulting in inactivation of the SHH/Dual‐specificity phosphatase 13B (DUSP13B)/p‐STAT3 and Hedgehog pathways, suppressing Myc proto‐oncogene protein (c‐Myc). Additionally, DUSP13B interacts with signal transducer and activator of transcription 3 (STAT3) and modulates its phosphorylation. Interestingly, it is observed that SHH overexpression partially rescues the synergistic effects of this combination treatment strategy through the SHH/DUSP13B/p‐STAT3 signaling axis. Moreover, it is found that SHH, (GLI1), p‐STAT3, and DUSP13B play significant predictive roles in osimertinib resistance. In lung adenocarcinoma, p‐STAT3 is positively correlated with SHH but negatively correlated with DUSP13B. Together, these results highlight the crucial role of itraconazole in reversing the acquired resistance to osimertinib and provide a scientific rationale for the therapeutic strategy of combining osimertinib with itraconazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
- Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis, Changsha, Hunan, 410011, China.
- Cancer Research Institute of Central South University, Changsha, Hunan, 410078, China.
ORCID-Profile: Songqing Fan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Hunan Provincial Health High-Level Talent Scientific Research Project
- National Key Clinical Specialty Scientific Research Project
Zitieren
APA
Zheng, H., Tang, Y., Zang, H., Luo, J., Zhou, H., Zhan, Y., Zou, Y., Wen, Q., Ma, J., & Fan, S. (2025). Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis. Advanced Science. https://doi.org/10.1002/advs.202409416
Vancouver
Zheng H, Tang Y, Zang H, Luo J, Zhou H, Zhan Y, et al. Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis. Advanced Science. 2025. doi:10.1002/advs.202409416
BibTeX
@article{Zheng2025,
author = {Zheng, Hongmei and Tang, Yaoxiang and Zang, Hongjing and Luo, Jiadi and Zhou, Hanqiong and Zhan, Yuting and Zou, Ying and Wen, Qiuyuan and Ma, Jian and Fan, Songqing},
title = {Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409416}
}
EUVIMED